NEW YORK (GenomeWeb News) – PerkinElmer said today that it has struck an assay development and sample testing collaboration with immunological reagents developer BioLegend.
The agreement will enable BioLegend to offer immunoassay development and bioanalytical testing based on PerkinElmer's AlphaLISA assay technology.
The homogenous, bead-based PerkinElmer technology is comprised of quantitative assays with ranges that are broader than standard enzyme-linked immunosorbent assays, and the company said it can save time in lab workflows and can eliminate wash steps that are difficult to automate. PerkinElmer also said that the technology allows for easy integration into automated high-throughput testing systems, such as its JANUS liquid handling system.
"Combining PerkinElmer's technologies with BioLegend's unique immunoassay development capabilities enables scientists to benefit from reduced barriers to discovery such as time or resource constraints," PerkinElmer's Bio-discovery President, Richard Eglen, said in a statement.